BioCentury
ARTICLE | Company News

CHMP recommendations include HBV drug Vemlidy

November 11, 2016 11:29 PM UTC

EMA's CHMP backed approval of a host of candidates on Friday, including Vemlidy tenofovir alafenamide fumarate (TAF; GS-7340) from Gilead Sciences Inc. (NASDAQ:GILD) to treat HBV.

CHMP recommended Vemlidy's approval to treat chronic HBV infection in patients aged 12 and older with a body weight of at least 35 kg. On Thursday, FDA approved the drug to treat chronic HBV infection in patients with compensated liver disease. It is a prodrug of tenofovir, a nucleotide analog prodrug reverse transcriptase inhibitor (see BioCentury Extra, Nov. 10)...